PSNL تصريحات هيئة الأوراق المالية والبورصات - Personalis, Inc.- التقرير السنوي، بيان التوكيل، نشرة الإصدار

الإحصائيات الأساسية

LEI	549300EZ2NYFK7H0US48
CIK	1527753

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Personalis, Inc.

SEC Filings (Chronological Order)

توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.

August 22, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2025 Personalis, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2025 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File N
August 5, 2025	EX-10.1	Personalis, Inc. 2020 Inducement Plan, as amended. Exhibit 10.1 Personalis, Inc. 2020 Inducement Plan Adopted by the Compensation Committee of the Board of Directors: May 4, 2020 Amended by the Compensation Committee of the Board of Directors: April 25, 2023 Amended by the Compensation Committee of the Board of Directors: April 29, 2025 1. General. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan
August 5, 2025	EX-99.1	Personalis Reports Second Quarter 2025 Financial Results Strong Q2 Clinical Momentum with 59% Sequential Growth in Test Volume EX-99.1 Exhibit 99.1 Personalis Reports Second Quarter 2025 Financial Results Strong Q2 Clinical Momentum with 59% Sequential Growth in Test Volume FREMONT, Calif. – August 5, 2025 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2025, and recent accomplishments of its “Win-in-MRD” strate
August 5, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Personalis, Inc.
August 5, 2025	S-8	As filed with the Securities and Exchange Commission on August 5, 2025 As filed with the Securities and Exchange Commission on August 5, 2025 Registration No.
August 5, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 Personalis, Inc. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File Nu
August 5, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38943 Personalis, Inc.
August 5, 2025	EX-99.1	Personalis, Inc. 2020 Inducement Plan, as amended EX-99.1 Exhibit 99.1 PERSONALIS, INC. 2020 INDUCEMENT PLAN ADOPTED BY THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS: MAY 4, 2020 AMENDED BY THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS: APRIL 25, 2023 AMENDED BY THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS: APRIL 29, 2025 1. GENERAL. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under t
July 9, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2025 Personalis, Inc. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2025 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File Numb
May 19, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2025 Personalis, Inc. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2025 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File Numb
May 6, 2025	EX-99.1	Personalis Reports First Quarter 2025 Financial Results Clinical test volume of 2,184 increased 52% sequentially Pharma tests and services of $13.6 million increased 39% year-over-year Exhibit 99.1 Personalis Reports First Quarter 2025 Financial Results Clinical test volume of 2,184 increased 52% sequentially Pharma tests and services of $13.6 million increased 39% year-over-year FREMONT, Calif. – May 6, 2025 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2025 ended March 31, 2025
May 6, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38943 Personalis, Inc.
May 6, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
April 3, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 3, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 1, 2025	CORRESP	PERSONALIS, INC. 6600 Dumbarton Circle Fremont, California 94555 CORRESP PERSONALIS, INC. 6600 Dumbarton Circle Fremont, California 94555 VIA EDGAR April 1, 2025 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attn: Jane Park Re: Personalis, Inc. Registration Statement on Form S-3 File No. 333-285379 Acceleration Request Requested Date: April 3, 2025
February 27, 2025	EX-19.1	Insider Trading Policy. Exhibit 19.1 Personalis, Inc. Insider Trading Policy Adopted by the Audit Committee of the Board of Directors: May 23, 2019 Last Amended by the Board of Directors: August 2, 2023 I. Introduction During the course of your relationship with Personalis, Inc. (together with its consolidated subsidiaries, “Personalis”), you may receive material information that is not yet publicly available (“material
February 27, 2025	EX-FILING FEES	Filing Fee Table EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Personalis, Inc.
February 27, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Personalis, Inc UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File
February 27, 2025	S-3	As filed with the Securities and Exchange Commission on February 27, 2025 Table of Contents As filed with the Securities and Exchange Commission on February 27, 2025 Registration No.
February 27, 2025	EX-99.1	Personalis Reports Fourth Quarter and Full Year 2024 Financial Results Full year revenue of $84.6 million represents a 15% year-over-year increase Cash balance of $185 million expected to provide runway to cash flow break-even Exhibit 99.1 Personalis Reports Fourth Quarter and Full Year 2024 Financial Results Full year revenue of $84.6 million represents a 15% year-over-year increase Cash balance of $185 million expected to provide runway to cash flow break-even FREMONT, Calif. – February 27, 2025 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results fo
February 27, 2025	EX-10.19	Amendment No. 3 to the Commercialization and Reference Laboratory Agreement, dated December 13, 2024, by and between the Registrant and Tempus AI, Inc. Exhibit 10.19 In accordance with Item 601(b)(10)(iv) of Regulation S-K, information indicated with “[***]” has been redacted because it is both not material and is the type that the registrant treats as private or confidential. Amendment No. 3 to the Commercialization and Reference Laboratory Agreement This Amendment No. 3 (“Amendment”) is made as of the date of the last signature below (“Amendmen
February 27, 2025	S-8	Power of Attorney (reference is made to the signature page hereto). S-8 As filed with the Securities and Exchange Commission on February 27, 2025 Registration No.
February 27, 2025	10-K	Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38943 Personalis, Inc. (Exact
February 27, 2025	EX-FILING FEES	Filing Fee Table. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) Personalis, Inc.
February 27, 2025	EX-21.1	Subsidiaries of the Registrant as of December 31, 2024. Exhibit 21.1 SUBSIDIARIES OF PERSONALIS, INC. Name of Subsidiary Jurisdiction of Incorporation Personalis (UK) Ltd. United Kingdom
January 7, 2025	EX-99.1	Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue Full year revenue of ~$84.6 million represents a 15% year-over-year increase Cash balance of ~$185.0 million expected to provide runway to cash flow break-even Exhibit 99.1 Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue Full year revenue of ~$84.6 million represents a 15% year-over-year increase Cash balance of ~$185.0 million expected to provide runway to cash flow break-even FREMONT, Calif. – January 7, 2025 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited prelim
January 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 Personalis, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File N
December 27, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2024 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File
December 27, 2024	EX-1.1	Amended and Restated At-the-Market Sales Agreement, dated December 27, 2024, by and among Personalis, Inc., Piper Sandler & Co. and BTIG, LLC. Exhibit 1.1 PERSONALIS, INC. SHARES OF COMMON STOCK (par value $0.0001 per share) AMENDED AND RESTATED AT-THE-MARKET SALES AGREEMENT December 27, 2024 Piper Sandler & Co. 800 Nicollet Mall, Suite 800 Minneapolis, Minnesota 55402 BTIG, LLC 350 Bush St, 9th Floor San Francisco, CA 94104 Ladies and Gentlemen: Personalis, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agre
December 27, 2024	424B5	Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-276204 Prospectus Supplement (To prospectus dated January 9, 2024) $50,000,000 Common Stock We have entered into an amended and restated at-the-market sales agreement (the “Sales Agreement”), with Piper Sandler & Co. (“Piper”) and BTIG, LLC (“BTIG”), relating to the sale of shares of our common stock offered by this prospectus
December 23, 2024	EX-99.1	Joint Filing Agreement Pursuant to Rule 13d-1 Exhibit 99.1 Joint Filing Agreement Pursuant to Rule 13d-1 This agreement is made pursuant to Rule 13d-l(k)(1) under the Securities and Exchange Act of 1934, as amended (the “Act”) by and among the parties listed below, each referenced to herein as a “Joint Filer.” The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the Rules thereu
December 19, 2024	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2024 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File
December 19, 2024	EX-4.1	Investment Agreement, dated December 19, 2024, by and between Personalis, Inc. and Merck Sharp & Dohme LLC. Exhibit 4.1 INVESTMENT AGREEMENT THIS INVESTMENT AGREEMENT (this “Agreement”), dated as of December 19, 2024, by and between Personalis, Inc., a Delaware corporation (the “Company”), and Merck Sharp & Dohme LLC, a Delaware limited liability company (the “Investor”). Capitalized terms used herein but not otherwise defined shall have the meanings given to them in Section 1.5. RECITALS A. On the ter
November 6, 2024	EX-99.1	Personalis Reports Third Quarter 2024 Financial Results 41% Year-over-Year Increase in Revenue Driven by Strong Biopharma Growth of 96% Raising 2024 Revenue Guidance Due to Accelerating Growth Cash Balance of $143.7 Million Extends Expected Runway In Exhibit 99.1 Personalis Reports Third Quarter 2024 Financial Results 41% Year-over-Year Increase in Revenue Driven by Strong Biopharma Growth of 96% Raising 2024 Revenue Guidance Due to Accelerating Growth Cash Balance of $143.7 Million Extends Expected Runway Into First-Half of 2027 FREMONT, Calif. – November 6, 2024 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision o
November 6, 2024	EX-10.2	Amendment No. 2 to the Commercialization and Reference Laboratory Agreement, dated September 20, 2024, by and between Personalis, Inc. and Tempus AI, Inc. Exhibit 10.2 Amendment No. 2 to the Commercialization and Reference Laboratory Agreement This Amendment No. 2 (“Amendment”) is made as of the date of the last signature below (“Amendment Date”) between Personalis, Inc. (“Personalis”) and Tempus AI, Inc. f/k/a Tempus Labs, Inc. (“Tempus”) and amends that certain Commercialization and Reference Laboratory Agreement with the effective date of Novembe
November 6, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38943 Personalis, Inc.
November 6, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File
September 19, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2024 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission Fil
September 9, 2024	CORRESP	PERSONALIS, INC. 6600 Dumbarton Circle Fremont, California 94555 CORRESP PERSONALIS, INC. 6600 Dumbarton Circle Fremont, California 94555 VIA EDGAR September 9, 2024 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attn: Robert Augustin Re: Personalis, Inc. Registration Statement on Form S-3 File No. 333-281886 Acceleration Request Requested Date: Sep
August 30, 2024	EX-FILING FEES	Filing Fee Table. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) Personalis, Inc.
August 30, 2024	S-3	As filed with the Securities and Exchange Commission on August 30, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on August 30, 2024 Registration No.
August 20, 2024	SC 13D/A	PSNL / Personalis, Inc. / Tempus Labs, Inc. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Personalis, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 71535D106 (CUSIP Number) Andrew Polovin 600 West Chicago Avenue, Suite 510 Chicago, Illinois 60654 (800) 976-5448 (Name, Address and Telephone Number of Pers
August 19, 2024	SC 13G/A	PSNL / Personalis, Inc. / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 Personalis, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 71535D106 (CUSIP Number) August 16, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule
August 16, 2024	EX-10.1	Amendment No. 1 to the Commercialization and Reference Laboratory Agreement, dated August 16, 2024, by and between Personalis, Inc. and Tempus AI, Inc. Exhibit 10.1 In accordance with Item 601(b)(10)(iv) of Regulation S-K, information indicated with “[***]” has been redacted because it is both not material and is the type that the registrant treats as private or confidential. Amendment No. 1 to the Commercialization and Reference Laboratory Agreement This Amendment No. 1 (“Amendment”) is made as of the date of the last signature below (“Amendment
August 16, 2024	EX-99.1	Personalis and Tempus Announce Expanded Collaboration Tempus invests $36 million by exercising warrants and purchasing additional shares Exhibit 99.1 Personalis and Tempus Announce Expanded Collaboration Tempus invests $36 million by exercising warrants and purchasing additional shares FREMONT, Calif. – August 16, 2024 – Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed in November 2023 to collaborate and bring ultra
August 16, 2024	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2024 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File N
August 16, 2024	EX-4.1	Investment Agreement, dated August 16, 2024, by and between Personalis, Inc. and Tempus AI, Inc. Exhibit 4.1 INVESTMENT AGREEMENT THIS INVESTMENT AGREEMENT (this “Agreement”), dated as of August 16, 2024, by and between Personalis, Inc., a Delaware corporation (the “Company”), and Tempus AI, Inc., a Delaware corporation (the “Investor”). Capitalized terms used herein but not otherwise defined shall have the meanings given to them in Section 1.5. RECITALS A. On the terms and subject to the con
August 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File Nu
August 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38943 Personalis, Inc.
August 7, 2024	EX-99.1	Personalis Reports Second Quarter 2024 Financial Results Strong Revenue Growth of 35% Year-over-Year Driven by 117% Growth from Biopharma Business Raises 2024 Full Year Revenue Guidance Exhibit 99.1 Personalis Reports Second Quarter 2024 Financial Results Strong Revenue Growth of 35% Year-over-Year Driven by 117% Growth from Biopharma Business Raises 2024 Full Year Revenue Guidance FREMONT, Calif. – August 7, 2024 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2024, an
July 26, 2024	SC 13G	PSNL / Personalis, Inc. / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Personalis, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 71535D106 (CUSIP Number) July 19, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed ☐ Rule 13d-
July 3, 2024	EX-1	Joint Filing Agreement. EX-1 2 ex1.htm Exhibit 1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concer
July 3, 2024	SC 13D	PSNL / Personalis, Inc. / Tempus Labs, Inc. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Personalis, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 71535D106 (CUSIP Number) Andrew Polovin 600 West Chicago Avenue, Suite 510 Chicago, Illinois 60654 (800) 976-5448 (Name, Address and Telephone Number of Perso
June 28, 2024	EX-99.4	JOINT FILING AGREEMENT EXHIBIT 99.4 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned agree that the Statement on Schedule 13D to which this exhibit is attached is filed on behalf of each of them in the capacities set forth below. Dated: June 28, 2024 Lightspeed Venture Partners VIII, L.P. By: Lightspeed General Partner VIII, L.P. Its:
June 28, 2024	SC 13D/A	PSNL / Personalis, Inc. / LIGHTSPEED VENTURE PARTNERS VIII LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Personalis, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 7153D 10 6 (CUSIP Number) Lightspeed Venture Partners VIII, L.P. c/o Lightspeed Venture Partners Attention: Andrew Moley 2200 Sand Hill Road Menlo P
June 27, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 Personalis, Inc. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File Num
June 27, 2024	EX-10.1	Settlement and License Agreement, between Personalis, Inc. and Foresight Diagnostics, Inc., dated June 21, 2024. Exhibit 10.1 In accordance with Item 601(b)(10)(iv) of Regulation S-K, information indicated with “[***]” has been redacted because it is both not material and is the type that the registrant treats as private or confidential. SETTLEMENT AND LICENSE AGREEMENT This Settlement and License Agreement (this “Agreement”) is entered into by and between Personalis, Inc., with a principal place of business
May 21, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2024 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File Numb
May 8, 2024	EX-10.1	Amended and Restated Non-Employee Director Compensation Policy, dated February 27, 2024 Exhibit 10.1 Personalis, Inc. Amended and Restated Non-Employee Director Compensation Policy Adopted by the Board of Directors: May 23, 2019 Last amended by the Board of Directors: February 27, 2024 Each member of the Board of Directors (the “Board”) of Personalis, Inc. (the “Company”) who is a non-employee director of the Company (each such member, a “Non-Employee Director”) will receive the comp
May 8, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
May 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38943 Personalis, Inc.
May 8, 2024	EX-99.1	Personalis Reports First Quarter 2024 Financial Results Raises full year revenue guidance due to greater pharma testing demand Exhibit 99.1 Personalis Reports First Quarter 2024 Financial Results Raises full year revenue guidance due to greater pharma testing demand FREMONT, Calif. – May 8, 2024 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2024 ended March 31, 2024, and provided recent business highlights. Recent Business
April 2, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 2, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
February 29, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Personalis, Inc.
February 29, 2024	S-8	As filed with the Securities and Exchange Commission on February 28, 2024 As filed with the Securities and Exchange Commission on February 28, 2024 Registration No.
February 28, 2024	EX-10.6	Form of Option Agreement under 2020 Inducement Plan. Exhibit 10.6 Personalis, Inc. Stock Option Grant Notice (2020 Inducement Plan) Personalis, Inc. (the “Company”), pursuant to its 2020 Inducement Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this Stock Option Grant Notice, in the Opt
February 28, 2024	EX-99.1	Personalis Reports Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 Personalis Reports Fourth Quarter and Full Year 2023 Financial Results FREMONT, Calif. – February 28, 2024 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights. Recent Business Highlights • Obtained final Medicare co
February 28, 2024	EX-10.13	Third Amended and Restated Executive Severance Agreement, dated September 25, 2023, between the Company and Aaron Tachibana. Exhibit 10.13 PERSONALIS, INC. THIRD AMENDED AND RESTATED EXECUTIVE SEVERANCE AGREEMENT This Third Amended and Restated Executive Severance Agreement (the “Agreement”), effective as of September 25, 2023, amends, supersedes and restates in its entirety that certain Second Amended and Restated Executive Severance Agreement by and between Aaron Tachibana (“Executive”) and Personalis, Inc. (the “Comp
February 28, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38943 Personalis, Inc. (Exact
February 28, 2024	EX-97	Incentive Compensation Recoupment Policy. Exhibit 97 PERSONALIS, INC. Incentive Compensation Recoupment Policy Adopted By the Compensation Committee of the Board of Directors: November 1, 2023 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Personalis, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its sto
February 28, 2024	EX-10.12	Second Amended and Restated Executive Severance Agreement, dated September 25, 2023, between the Company and Christopher Hall. Exhibit 10.12 PERSONALIS, INC. SECOND AMENDED AND RESTATED EXECUTIVE SEVERANCE AGREEMENT This Second Amended and Restated Executive Severance Agreement (the “Agreement”) effective as of September 25, 2023, amends, supersedes and restates in its entirety that certain First Amended and Restated Executive Severance Agreement by and between Christopher Hall (“Executive”) and Personalis, Inc. (the “Com
February 28, 2024	EX-10.15	Second Amended and Restated Executive Severance Agreement, dated September 18, 2023, between the Company and Stephen Moore. Exhibit 10.15 PERSONALIS, INC. Second AMENDED AND RESTATED EXECUTIVE SEVERANCE AGREEMENT (Senior Vice President, Vice President, or Equivalent Individual Contributor) This Second Amended and Restated Executive Severance Agreement (the “Agreement”), effective as of September 18, 2023, amends, supersedes and restates in its entirety that certain First Amended and Restated Executive Severance Agreeme
February 28, 2024	EX-10.5	Form of RSU Award Agreement under 2020 Inducement Plan. Exhibit 10.5 Personalis, Inc. Restricted Stock Unit Grant Notice (2020 Inducement Plan) Personalis, Inc. (the “Company”), pursuant to its 2020 Inducement Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award is subject to all of the terms and conditions
February 28, 2024	EX-21.1	Subsidiaries of the Registrant as of December 31, 2023. Exhibit 21.1 SUBSIDIARIES OF PERSONALIS, INC. Name of Subsidiary Jurisdiction of Incorporation Personalis (UK) Ltd. United Kingdom Shanghai Personalis Biotechnology Co., Ltd. China
February 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Personalis, Inc UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File
February 28, 2024	EX-10.4	Personalis, Inc. 2020 Inducement Plan, as amended. Exhibit 10.4 Personalis, Inc. 2020 Inducement Plan Adopted by the Compensation Committee of the Board of Directors: May 4, 2020 Amended by the Compensation Committee of the Board of Directors: April 25, 2023 1. General. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Ma
February 28, 2024	EX-10.14	Third Amended and Restated Executive Severance Agreement, dated September 25, 2023, between the Company and Richard Chen. Exhibit 10.14 PERSONALIS, INC. THIRD AMENDED AND RESTATED EXECUTIVE SEVERANCE AGREEMENT This Third Amended and Restated Executive Severance Agreement (the “Agreement”), effective as of September 25, 2023, amends, supersedes and restates in its entirety that certain Second Amended and Restated Executive Severance Agreement by and between Dr. Richard Chen (“Executive”) and Personalis, Inc. (the “Com
January 29, 2024	SC 13G/A	PSNL / Personalis, Inc. / ARK Investment Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm244117d21sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* Personalis, Inc. (Name of Issuer) Common stock (Title of Class of Securities) 71535D106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat
January 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 Personalis, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File N
January 5, 2024	EX-99.1	Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance Exhibit 99.1 Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance FREMONT, CA - Jan. 5, 2024 - (BUSINESS WIRE) - Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2023. Preliminary Fourth Quarter Revenue and Cash Balance • Pr
January 5, 2024	CORRESP	PERSONALIS, INC. 6600 Dumbarton Circle Fremont, California 94555 PERSONALIS, INC. 6600 Dumbarton Circle Fremont, California 94555 VIA EDGAR January 5, 2024 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attn: J. Conlon Danberg Re: Personalis, Inc. Registration Statement on Form S-3 File No. 333-276204 Acceleration Request Requested Date: January 9,
January 4, 2024	CORRESP	Cooley LLP 1700 Seventh Avenue Suite 1900 Seattle, WA 98101-1355 t: +1 206 452 8700 f: +1 206 452 8800 cooley.com Laura Berezin +1 206 452 8775 [email protected] January 4, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attn: J. Conlon Danberg RE: Personalis, Inc. Registration Statement on Form S-3 Filed December 21, 2023 File No. 333-276204 Ladies and Gentlemen: On behalf of Pers
January 4, 2024	CORRESP	PERSONALIS, INC. 6600 Dumbarton Circle Fremont, California 94555 PERSONALIS, INC. 6600 Dumbarton Circle Fremont, California 94555 VIA EDGAR January 4, 2024 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attn: J. Conlon Danberg Re: Personalis, Inc. Registration Statement on Form S-3 File No. 333-276206 Acceleration Request Requested Date: January 8,
December 21, 2023	EX-4.8	Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.8 PERSONALIS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF PERSONALIS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between PERSONALIS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws
December 21, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Personalis, Inc.
December 21, 2023	S-3	As filed with the Securities and Exchange Commission on December 21, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on December 21, 2023 Registration No.
December 21, 2023	EX-4.9	Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.9 PERSONALIS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF PERSONALIS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between PERSONALIS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws
December 21, 2023	EX-4.5	Form of Indenture, between the Registrant and one or more trustees to be named. Exhibit 4.5 PERSONALIS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20[•] Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Section
December 21, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) Personalis, Inc.
December 21, 2023	S-3	As filed with the Securities and Exchange Commission on December 21, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on December 21, 2023 Registration No.
December 21, 2023	EX-4.7	Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.7 PERSONALIS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF PERSONALIS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between PERSONALIS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] a
December 21, 2023	EX-1.3	Amendment No. 1 to At-the-Market Sales Agreement, dated December 21, 2023, by and between the Registrant and BTIG, LLC. Exhibit 1.3 PERSONALIS, INC. Shares of Common Stock ($0.0001 par value) AMENDMENT NO. 1 TO THE AT-THE-MARKET SALES AGREEMENT December 21, 2023 BTIG, LLC 600 Montgomery Street, 6th Floor San Francisco, CA 94111 Ladies and Gentlemen: Reference is made to the At-the-Market Sales Agreement, dated December 30, 2021 (the “Agreement”), by and between Personalis, Inc., a Delaware corporation (the “Company
December 7, 2023	SC 13G/A	PSNL / Personalis Inc / JPMORGAN CHASE & CO - FILING PERSONALIS, INC. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 03)* Personalis, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 71535D106 (CUSIP Number) November 30, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r
December 5, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2023 Personalis, Inc UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2023 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File
December 5, 2023	SC 13G	PSNL / Personalis Inc / Tempus Labs, Inc. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. )* Under the Securities Exchange Act of 1934 Personalis, Inc. (Name of Issuer) Common Stock (Titles of Class of Securities) 71535D106 (CUSIP Number) November 28, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
December 1, 2023	8-K	Regulation FD Disclosure, Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2023 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File
November 28, 2023	EX-4.2	Warrant to Purchase Shares of Common Stock of Personalis, Inc., dated November 28, 2023, and expiring December 31, 2025 (incorporated by reference to Exhibit 4.2 to the Issuer’s Current Report on Form 8-K filed with the SEC on November 28, 2023) Exhibit 4.2 EXECUTION COPY THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATES IN THE UNITED STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE TERMS
November 28, 2023	EX-4.1	Warrant to Purchase Shares of Common Stock of Personalis, Inc., dated November 28, 2023, and expiring December 31, 2024 (incorporated by reference to Exhibit 4.1 to the Issuer’s Current Report on Form 8-K filed with the SEC on November 28, 2023) Exhibit 4.1 EXECUTION COPY THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATES IN THE UNITED STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE TERMS
November 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2023 Personalis, Inc UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2023 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File
November 28, 2023	EX-10.1	Commercialization and Reference Laboratory Agreement, between Personalis, Inc. and Tempus Labs, Inc., dated November 25, 2023 (incorporated by reference to Exhibit 10.1 to the Issuer’s Current Report on Form 8-K filed with the SEC on November 28, 2023) Exhibit 10.1 In accordance with Item 601(b)(10)(iv) of Regulation S-K, information indicated with “[***]” has been redacted because it is both not material and is the type that the registrant treats as private or confidential. Commercialization and Reference Laboratory Agreement This Commercialization and Reference Laboratory Agreement (“Agreement”) is entered into by and between Tempus Labs, Inc.
November 7, 2023	EX-99.1	Personalis Reports Third Quarter 2023 Financial Results Increased third quarter revenue 23% to $18.2 million and increased full year guidance Presented data supporting Next Personal’s market leading sensitivity for cancer recurrence detection Exhibit 99.1 Personalis Reports Third Quarter 2023 Financial Results Increased third quarter revenue 23% to $18.2 million and increased full year guidance Presented data supporting Next Personal’s market leading sensitivity for cancer recurrence detection FREMONT, Calif. – November 7, 2023 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported finan
November 7, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38943 Personalis, Inc.
November 7, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File
August 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2023 Personalis, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2023 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File N
August 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38943 Personalis, Inc.
August 8, 2023	EX-99.1	Personalis Reports Second Quarter 2023 Financial Results Exhibit 99.1 Personalis Reports Second Quarter 2023 Financial Results FREMONT, Calif. – August 8, 2023 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2023 and provided recent business highlights. Recent Business Updates • Announced a collaboration with National Cancer Center Hospital Ea
August 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 Personalis, Inc. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File Nu
June 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 Personalis, Inc. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File Num
June 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 Personalis, Inc. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File Numb
June 9, 2023	EX-16.1	Letter from Deloitte & Touche LLP, dated June 9, 2023. Exhibit 16.1 June 9, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 Dear Sirs/Madams: We have read Item 4.01 of Personalis, Inc.’s Form 8-K dated June 9, 2023, and have the following comments: 1. We agree with the statements made in part (a) Dismissal of Independent Registered Public Accounting Firm. 2. We have no basis on which to agree or disagree with the
May 19, 2023	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File Numb
May 15, 2023	EX-FILING FEES	Filing Fee Table EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Personalis, Inc.
May 15, 2023	S-8	As filed with the Securities and Exchange Commission on May 15, 2023 S-8 As filed with the Securities and Exchange Commission on May 15, 2023 Registration No.
May 3, 2023	EX-10	Amended and Restated Non-Employee Director Compensation Policy, dated March 2, 2023. Exhibit 10.1 Personalis, Inc. Amended and Restated Non-Employee Director Compensation Policy Adopted by the Board of Directors: May 23, 2019 Last amended by the Board of Directors: March 2, 2023 Each member of the Board of Directors (the “Board”) of Personalis, Inc. (the “Company”) who is a non-employee director of the Company (each such member, a “Non-Employee Director”) will receive the compensa
May 3, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38943 Personalis, Inc.
May 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 Personalis, Inc. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
May 3, 2023	EX-99	Personalis Reports First Quarter 2023 Financial Results Exhibit 99.1 Personalis Reports First Quarter 2023 Financial Results FREMONT, Calif. – May 3, 2023 –Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter ended March 31, 2023 and provided recent business highlights. Recent Business Updates • Announced a collaboration with Cancer Research UK, University College
April 5, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte
April 5, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule
March 8, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File Num
March 8, 2023	EX-10.1	Amended and Restated Employment Agreement dated March 7, 2023, between the Company and Aaron Tachibana. EX-10.1 Exhibit 10.1 March 7, 2023 Aaron Tachibana Re: First Amended and Restated Employment Terms Dear Aaron, This First Amended and Restated Employment Terms letter agreement (“Agreement”) between Personalis, Inc. (“Personalis” or “Company”) and you supersedes in its entirety and restates that certain Employment Terms letter agreement between you and Personalis dated June 2, 2019 (the “Prior Agr
March 8, 2023	EX-10.2	Amended and Restated Offer Letter, dated March 7, 2023, between the Company and Christopher Hall. EX-10.2 Exhibit 10.2 March 7, 2023 Christopher Hall San Francisco, CA 94115 [email protected] Re: First Amended and Restated Offer Letter Agreement Dear Chris, This First Amended and Restated offer letter agreement between Personalis, Inc. (“Personalis” or “Company”) and you supersedes in its entirety and restates that certain offer letter agreement between you and Personalis dated September
March 8, 2023	EX-10.4	Second Amended and Restated Executive Severance Agreement, dated March 7, 2023, between the Company and Aaron Tachibana EX-10.4 Exhibit 10.4 PERSONALIS, INC. SECOND AMENDED AND RESTATED EXECUTIVE SEVERANCE AGREEMENT This Second Amended and Restated Executive Severance Agreement (the “Agreement”), effective as of March 7, 2023, amends, supersedes and restates in its entirety that certain First Amended and Restated Executive Severance Agreement by and between Aaron Tachibana (“Executive”) and Personalis, Inc. (the “C
March 8, 2023	EX-10.5	First Amended and Restated Executive Severance Agreement, dated March 7, 2023, between the Company and Christopher Hall EX-10.5 Exhibit 10.5 PERSONALIS, INC. FIRST AMENDED AND RESTATED EXECUTIVE SEVERANCE AGREEMENT This First Amended and Restated Executive Severance Agreement (the “Agreement”) effective as of March 7, 2023, amends, supersedes and restates in its entirety that certain Executive Severance Agreement by and between Christopher Hall (“Executive”) and Personalis, Inc. (the “Company”) dated November 9, 20
March 8, 2023	EX-10.3	Amended and Restated Employment Agreement dated March 8, 2023, between the Company and Richard Chen. EX-10.3 Exhibit 10.3 March 7, 2023 Dr. Richard Chen Re: First Amended and Restated Employment Terms Dear Richard, This First Amended and Restated Employment Terms letter agreement (“Agreement”) between Personalis, Inc. (“Personalis” or “Company”) and you supersedes in its entirety and restates that certain Employment Terms letter agreement between you and Personalis dated June 2, 2019 (the “Prior
March 8, 2023	EX-10.6	Second Amended and Restated Executive Severance Agreement, dated March 8, 2023, between the Company and Richard Chen EX-10.6 Exhibit 10.6 PERSONALIS, INC. SECOND AMENDED AND RESTATED EXECUTIVE SEVERANCE AGREEMENT This Second Amended and Restated Executive Severance Agreement (the “Agreement”), effective as of March 8, 2023, amends, supersedes and restates in its entirety that certain First Amended and Restated Executive Severance Agreement by and between Dr. Richard Chen (“Executive”) and Personalis, Inc. (the “
February 23, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File
February 23, 2023	10-K	Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38943 Personalis, Inc. (Exact
February 23, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Personalis, Inc.
February 23, 2023	EX-10	Amendment No. 3 to Lease, by and between Ardenwood Ventures I, LLC and the Registrant, dated December 19, 2022. AMENDMENT NO. 3 TO LEASE This Amendment No. 3 To Lease (“Amendment”) is dated as of December 19, 2022 (the “Amendment Date”) by and between Ardenwood Ventures I, LLC, a Delaware limited liability company (“Landlord”), and Personalis, Inc., a Delaware corporation (“Tenant”). Recitals A. Landlord and Tenant entered into that certain Lease Agreement dated as of August 24, 2021, as amended by that cer
February 23, 2023	S-8	As filed with the Securities and Exchange Commission on February 23, 2023 S-8 As filed with the Securities and Exchange Commission on February 23, 2023 Registration No.
February 23, 2023	EX-99	Personalis Reports Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 Personalis Reports Fourth Quarter and Full Year 2022 Financial Results FREMONT, Calif. – February 23, 2023 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided recent business highlights. Recent Business Highlights • Announced a continuing par
February 23, 2023	EX-21	Subsidiaries of the Registrant as of December 31, 2022. Exhibit 21.1 SUBSIDIARIES OF PERSONALIS, INC. Name of Subsidiary Jurisdiction of Incorporation Personalis (UK) Ltd. United Kingdom Shanghai Personalis Biotechnology Co., Ltd. China
February 10, 2023	SC 13G/A	PSNL / Personalis Inc / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
January 25, 2023	SC 13G/A	PSNL / Personalis Inc / JPMORGAN CHASE & CO - FILING PERSONALIS, INC. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 02)* Personalis, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 71535D106 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r
January 18, 2023	8-K	Regulation FD Disclosure, Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2023 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File
January 4, 2023	EX-99.1	Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Exhibit 99.1 Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue FREMONT, Calif. ? January 4, 2023 ? Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2022. Personalis estimates revenue of approximately $16.7 million for the fourth quarter o
January 4, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2023 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File N
December 14, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File
December 14, 2022	EX-10.1	Separation Agreement, dated December 14, 2022, between John West and the Registrant. Exhibit 10.1 December 14, 2022 John West Via EMAIL/DOCUSIGN Dear John: This letter sets forth the substance of the separation agreement (the ?Agreement?) between you and Personalis, Inc. (the ?Company?). 1. SEPARATION. You hereby resign from all positions you hold with the Company (both as an employee and as a member of the Board of Directors (the ?Board?)), and the Company hereby accepts such res
November 16, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2022 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File
November 2, 2022	EX-10.1	Contract No. 36C24E22D0031, by and between the U.S. Department of Veterans Affairs and the Registrant, dated September 30, 2022. Exhibit 10.1 Page 1 of NUMPAGES \* Arabic \* MERGEFORMAT 41 Table of Contents SECTION A 1 A.1 SF 1449 SOLICITATION/CONTRACT/ORDER FOR COMMERCIAL PRODUCTS AND COMMERCIAL SERVICES Section B - CONTINUATION OF SF 1449 BLOCKS 3 B.1 CONTRACT ADMINISTRATION DATA 3 B.2 PRICE/COST SCHEDULE 9 ITEM INFORMATION 9 ACCOUNTING AND APPROPRIATION DATA 20 Section C - CONTRACT CLAUSES 21 C.1 52.212-4 CONTRACT TERMS
November 2, 2022	EX-99.1	Personalis Reports Third Quarter 2022 Financial Results Exhibit 99.1 Personalis Reports Third Quarter 2022 Financial Results MENLO PARK, Calif. ? November 2, 2022? Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2022. Third Quarter and Recent Highlights ? Reported quarterly revenue of $14.9 million in the third quarter of 2022 compared with
November 2, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File
November 2, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38943 Personalis, Inc.
October 31, 2022	EX-3.1	Amended and Restated Bylaws of the Registrant. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF Personalis, inC. (A DELAWARE CORPORATION) October 26, 2022 Table of Contents Page ARTICLE I Offices 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II Corporate Seal 1 Section 3. Corporate Seal 1 ARTICLE III Stockholders? Meetings 1 Section 4. Place of Meetings 1 Section 5. Annual Meetings. 2 Section 6. Special Meetings 6 Section 7. No
October 31, 2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2022 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File
October 3, 2022	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission Fil
August 3, 2022	EX-99.1	Personalis Reports Second Quarter 2022 Financial Results EX-99.1 2 psnl-ex9916.htm EX-99.1 Exhibit 99.1 Personalis Reports Second Quarter 2022 Financial Results MENLO PARK, Calif. – August 3, 2022 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2022. Second Quarter and Recent Highlights • Reported quarterly revenue of $18.2 million in the seco
August 3, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38943 Personalis, Inc.
August 3, 2022	EX-10.1	Amendment No. 2 to Lease, by and between Ardenwood Ventures I, LLC and the Registrant, dated June 9, 2022. Exhibit 10.1 AMENDMENT NO. 2 TO LEASE This AMENDMENT NO. 2 TO LEASE (?Amendment?) is dated as of June 9, 2022 (the ?Amendment Date?) by and between ARDENWOOD VENTURES I, LLC, a Delaware limited liability company (?Landlord?), and PERSONALIS, INC., a Delaware corporation (?Tenant?). Recitals A.Landlord and Tenant entered into that certain Lease Agreement dated as of August 24, 2021, as amended by t
August 3, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File Nu
May 19, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2022 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File Numb
May 4, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
May 4, 2022	EX-99.1	Personalis Reports First Quarter 2022 Financial Results Exhibit 99.1 Personalis Reports First Quarter 2022 Financial Results MENLO PARK, Calif. ? May 4, 2022 ? Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter ended March 31, 2022. First Quarter and Recent Highlights ? Reported quarterly revenue of $15.2 million in the first quarter of 2022 compared with $20.9 m
May 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38943 Personalis, Inc.
May 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
April 1, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitte
April 1, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 25, 2022	EX-99.1	Diagnostic Industry Veteran Karin Eastham to Chair Personalis Board of Directors Personalis’ oncology diagnostics business expected to build on foundation of advanced technology already the driver of rapidly growing revenue from pharmaceutical compan Exhibit 99.1 Diagnostic Industry Veteran Karin Eastham to Chair Personalis Board of Directors Personalis? oncology diagnostics business expected to build on foundation of advanced technology already the driver of rapidly growing revenue from pharmaceutical companies MENLO PARK, Calif.?(BUSINESS WIRE)?Mar. 24, 2022?Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncolog
March 25, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File Nu
March 7, 2022	SC 13D/A	PSNL / Personalis Inc / LIGHTSPEED VENTURE PARTNERS VIII LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Personalis, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 7153D 10 6 (CUSIP Number) Lightspeed Venture Partners VIII, L.P. c/o Lightspeed Venture Partners Attention: Andrew Moley 2200 Sand Hill Road Menlo
March 7, 2022	EX-99.3	JOINT FILING AGREEMENT EXHIBIT 99.3 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned agree that the Statement on Schedule 13D to which this exhibit is attached is filed on behalf of each of them in the capacities set forth below. Dated: March 7, 2022 Lightspeed Venture Partners VIII, L.P. By: Lightspeed General Partner VIII, L.P. Its:
February 24, 2022	EX-10.21	Amended and Restated Executive Severance Agreement, by and between Aaron Tachibana and the Registrant, dated February 23, 2022. Exhibit 10.21 PERSONALIS, INC. FIRST AMENDED AND RESTATED EXECUTIVE SEVERANCE AGREEMENT (Senior Vice President, Vice President, or Equivalent Individual Contributor) This First Amended and Restated Executive Severance Agreement (the ?Agreement?), effective as of February 23, 2022, amends, supersedes and restates in its entirety that certain Executive Severance Agreement by and between Aaron Tachib
February 24, 2022	EX-10.16	Amendment No. 1 to Lease, by and between Ardenwood Ventures I, LLC and the Registrant, dated December 8, 2021. Exhibit 10.16 AMENDMENT NO. 1 TO LEASE This AMENDMENT NO. 1 TO LEASE (?Amendment?) is dated as of this 8th day of December, 2021, by and between ARDENWOOD VENTURES I, LLC, a Delaware limited liability company (?Landlord?), and PERSONALIS, INC., a Delaware corporation (?Tenant?). RECITALS A.Landlord and Tenant entered into that certain Lease Agreement dated as of August 24, 2021 (the ?Lease?) for p
February 24, 2022	EX-10.20	Amended and Restated Executive Severance Agreement, by and between Dr. Richard Chen and the Registrant, dated February 23, 2022. Exhibit 10.20 PERSONALIS, INC. FIRST AMENDED AND RESTATED EXECUTIVE SEVERANCE AGREEMENT (Senior Vice President, Vice President, or Equivalent Individual Contributor) This First Amended and Restated Executive Severance Agreement (the ?Agreement?), effective as of February 23, 2022, amends, supersedes and restates in its entirety that certain Executive Severance Agreement by and between Dr. Richard
February 24, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107.1 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Personalis, Inc. Newly Registered Securities Title of Securities to be Registered Amount to be Registered (1) Proposed Maximum Offering Price per Share Proposed Maximum Aggregate Offering Price Amount of Registration Fee Common Stock, par value $0.0001 per share ? 2019 Equity Incentive Plan 2,245,226(2) $9.47(4) $21,262,290.22(4)
February 24, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File
February 24, 2022	EX-10.19	Amended and Restated Executive Severance Agreement, by and between John West and the Registrant, dated February 23, 2022. Exhibit 10.19 PERSONALIS, INC. FIRST AMENDED AND RESTATED EXECUTIVE SEVERANCE AGREEMENT (John West) This First Amended and Restated Executive Severance Agreement (the ?Agreement?), effective as of February 23, 2022 amends, supersedes and restates in its entirety that certain Executive Severance Agreement by and between John West (?Executive?) and Personalis, Inc. (the ?Company?) dated June 2, 2019
February 24, 2022	EX-21.1	Subsidiaries of the Registrant as of December 31, 2021. Exhibit 21.1 SUBSIDIARIES OF PERSONALIS, INC. Name of Subsidiary Jurisdiction of Incorporation Personalis (UK) Ltd. United Kingdom Shanghai Personalis Biotechnology Co., Ltd. China
February 24, 2022	EX-99.1	PERSONALIS, INC. Exhibit 99.1 Personalis Reports Fourth Quarter and Full Year 2021 Financial Results MENLO PARK, Calif. ? February 24, 2022 ? Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter and Recent Highlights ? Reported quarterly revenue of $20.7 million in the fou
February 24, 2022	EX-99.1	Consent to be Named as a Director Nominee of Oliva Bloom. Exhibit 99.1 CONSENT OF DIRECTOR NOMINEE I hereby consent to being named as a person who will be appointed to the Board of Directors of Personalis, Inc., a Delaware corporation (the "Company"), and to all other references to me, in the Company?s Annual Report on Form 10-K for the year ended December 31, 2021 to be filed with the U.S. Securities and Exchange Commission on February 24, 2022 on Form
February 24, 2022	EX-10.18	Amended Personalis, Inc. Non-Employee Director Compensation Policy, dated February 17, 2022. Exhibit 10.18 Personalis, Inc. Non-Employee Director Compensation Policy Amended by the Board of Directors: February 17, 2022 Each member of the Board of Directors (the ?Board?) of Personalis, Inc. (the ?Company?) who is a non-employee director of the Company (each such member, a ?Non-Employee Director?) will receive the compensation described in this Non-Employee Director Compensation Policy (the
February 24, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38943 Personalis, Inc. (Exact na
February 24, 2022	S-8	As filed with the Securities and Exchange Commission on February 24, 2022 As filed with the Securities and Exchange Commission on February 24, 2022 Registration No.
February 9, 2022	SC 13G/A	PSNL / Personalis Inc / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
January 14, 2022	SC 13G/A	PSNL / Personalis Inc / JPMORGAN CHASE & CO - FILING PERSONALIS, INC. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* Personalis, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 71535D106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r
January 6, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2022 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File N
January 6, 2022	EX-99.1	PERSONALIS, INC. Exhibit 99.1 Personalis Reports Preliminary Fourth Quarter and Full Year 2021 Revenue MENLO PARK, Calif. ? January 6, 2022 ? Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer and population sequencing, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2021. Personalis estimates revenue of approximately $20.7 million for the
January 3, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2021 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File
January 3, 2022	424B5	Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-251824 Prospectus Supplement (To prospectus dated January 8, 2021) $100,000,000 Common Stock We have entered into an at-the-market Sales Agreement (the ?Sales Agreement?), with BTIG, LLC (?BTIG?), relating to the sale of shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accord
January 3, 2022	EX-1.1	At-the-Market Sales Agreement, dated December 30, 2021, by and between the Registrant and BTIG, LLC. Exhibit 1.1 PERSONALIS, INC. UP TO $100,000,000 OF COMMON STOCK (par value $0.0001 per share) AT-THE-MARKET SALES AGREEMENT December 30, 2021 BTIG, LLC 600 Montgomery Street, 6th Floor San Francisco, California 94111 Ladies and Gentlemen: Personalis, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with BTIG, LLC (?BTIG? and, together with the Company, the ?P
November 4, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38943 Personalis, Inc.
November 4, 2021	EX-99.1	3 PERSONALIS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (in thousands, except share and per share data) Exhibit 99.1 Personalis Reports Third Quarter 2021 Financial Results MENLO PARK, Calif. ? November 4, 2021 ? Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer and population sequencing, today reported financial results for the third quarter ended September 30, 2021. Third Quarter and Recent Highlights ? Reported quarterly revenue of $22.3 million in the third quarter of 202
November 4, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File
November 4, 2021	EX-10.1	Lease, by and between Ardenwood Ventures I, LLC and the Registrant, dated August 25, 2021. LEASE BY AND BETWEEN Ardenwood Ventures I, LLC, a Delaware limited liability company as Landlord and Personalis, Inc.
August 25, 2021	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2021 Personalis, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2021 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File N
August 4, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38943 Personalis, Inc.
August 4, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File Nu
August 4, 2021	EX-99.1	3 PERSONALIS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (in thousands, except share and per share data) Exhibit 99.1 Personalis Reports Second Quarter 2021 Financial Results MENLO PARK, Calif. ? August 4, 2021 ? Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer and population sequencing, today reported financial results for the second quarter ended June 30, 2021. Second Quarter and Recent Highlights ? Record quarterly revenue of $21.7 million in the second quarter of 2021 com
May 19, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2021 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File Numb
May 5, 2021	EX-99.1	3 PERSONALIS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (in thousands, except share and per share data) Exhibit 99.1 Personalis Reports First Quarter 2021 Financial Results MENLO PARK, Calif. ? May 5, 2021 ? Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the first quarter ended March 31, 2021. First Quarter Highlights ? Record quarterly revenue of $20.9 million in the first quarter of 2021 compared with $19.2
May 5, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
May 5, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38943 Personalis, Inc.
April 1, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 1, 2021	DEF 14A	Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitte
March 8, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2021 (March 4, 2021) Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Com
February 25, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38943 Personalis, Inc. (Exact na
February 25, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File
February 25, 2021	EX-21.1	Subsidiaries of the Registrant as of December 31, 2020. Exhibit 21.1 SUBSIDIARIES OF PERSONALIS, INC. Name of Subsidiary Jurisdiction of Incorporation Personalis (UK) Ltd. United Kingdom Shanghai Personalis Biotechnology Co., Ltd. China
February 25, 2021	EX-99.1	3 PERSONALIS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) Exhibit 99.1 Personalis Reports Fourth Quarter and Full Year 2020 Financial Results MENLO PARK, Calif. – February 25, 2021 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2020. Fourth Quarter Highlights • Record quarterly revenue of $20.2 million in the fo
February 25, 2021	EX-4.1	Exhibit 4.1 Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Personalis, Inc. (?we,? ?our,? ?us,? or the ?Company?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our common stock. The following summary of the terms of our common stock is based upon o
February 25, 2021	S-8	Form S-8 As filed with the Securities and Exchange Commission on February 25, 2021 Registration No.
February 25, 2021	EX-10.17	Personalis, Inc. Non-Employee Director Compensation Policy. Exhibit 10.17 Personalis, Inc. Non-Employee Director Compensation Policy Amended by the Board of Directors: February 17, 2021 Each member of the Board of Directors (the ?Board?) of Personalis, Inc. (the ?Company?) who is a non-employee director of the Company (each such member, a ?Non-Employee Director?) will receive the compensation described in this Non-Employee Director Compensation Policy (the
February 16, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Personalis, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 71535D106 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul
January 27, 2021	EX-1.1	Underwriting Agreement, dated January 26, 2021, by and among the Company, Morgan Stanley & Co. LLC, BofA Securities, Inc., Citigroup Global Markets Inc., and Cowen and Company, LLC, as representatives of the several underwriters named on Schedule I thereto. EX-1.1 2 d109602dex11.htm EX-1.1 Exhibit 1.1 3,950,000 Shares PERSONALIS, INC. COMMON STOCK, $0.0001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT January 26, 2021 January 26, 2021 Morgan Stanley & Co. LLC BofA Securities, Inc. Citigroup Global Markets Inc. Cowen and Company, LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o BofA Securities, Inc. One Bryant Park New York, Ne
January 27, 2021	424B5	3,950,000 SHARES COMMON STOCK 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-251824 Prospectus Supplement (To Prospectus dated January 8, 2021) 3,950,000 SHARES COMMON STOCK We are offering 3,950,000 shares of our common stock. Our shares trade on the Nasdaq Global Market under the symbol “PSNL.” On January 26, 2021, the last reported sale price of our common stock was $42.47 per share. We are an
January 27, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2021 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission F
January 26, 2021	424B5	$150,000,000 COMMON STOCK 424B5 Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed.
January 15, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Personalis, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) (CUSIP N Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Personalis, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 71535D106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul
January 11, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K PRELIMINARY RESULTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File
January 11, 2021	EX-99.1	3 PERSONALIS, INC. PRELIMINARY REVENUE RESULTS (unaudited) (in thousands) Exhibit 99.1 Personalis Reports Preliminary Fourth Quarter 2020 Revenue MENLO PARK, Calif. – January 11, 2021 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2020. Personalis estimates revenue of approximately $20.2 million for the fourth quart
January 11, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Personalis, Inc. (Name of Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
January 6, 2021	CORRESP	- CORRESP PERSONALIS, INC. 1330 O’Brien Drive Menlo Park, California 94025 (650) 752-1300 January 6, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Personalis, Inc. Registration Statement on Form S-3 Filed December 30, 2020 File No. 333-251824 Ladies and Gentlemen: In accordance wit
December 30, 2020	S-3	- S-3 S-3 Table of Contents As filed with the U.S. Securities and Exchange Commission on December 30, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Personalis, Inc. (Exact name of registrant as specified in its charter) Delaware 27-5411038 (State or other jurisdiction of incorporation or
December 30, 2020	EX-4.4	Form of Indenture. EX-4.4 Exhibit 4.4 PERSONALIS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities. 5 Section 2.02 Form of Securities and Trustee’s Certificate. 8
December 30, 2020	EX-4.6	Form of Common Stock Warrant Agreement and Warrant Certificate. EX-4.6 Exhibit 4.6 PERSONALIS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF PERSONALIS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between PERSONALIS, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws o
December 30, 2020	EX-4.7	Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.7 4 d84047dex47.htm EX-4.7 Exhibit 4.7 PERSONALIS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF PERSONALIS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between PERSONALIS, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organ
December 30, 2020	EX-4.8	Form of Debt Securities Warrant Agreement and Warrant Certificate. EX-4.8 Exhibit 4.8 PERSONALIS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF PERSONALIS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between PERSONALIS, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under t
November 10, 2020	SC 13G	PSNL / Personalis, Inc. / ARK Investment Management LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
November 5, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38943 Personalis, Inc.
November 5, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File
November 5, 2020	EX-99.1	3 PERSONALIS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (in thousands, except share and per share data) Exhibit 99.1 Personalis Reports Third Quarter 2020 Financial Results MENLO PARK, Calif. – November 5, 2020 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the third quarter ended September 30, 2020. Third Quarter Highlights • Reported record revenues of $19.8 million in the third quarter of 2020 versus $17.
August 24, 2020	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 a20-292281ex99d1.htm EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned agree that the Statement on Schedule 13D to which this exhibit is attached is filed on behalf of each of them in the capacities set forth below. Dated: August 24, 2020 Lightspeed Venture Partners VIII, L.P. By: Li
August 24, 2020	SC 13D	PSNL / Personalis, Inc. / LIGHTSPEED VENTURE PARTNERS VIII LP - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Personalis, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 7153D 10 6 (CUSIP Number) Lightspeed Venture Partners VIII, L.P. c/o Lightspeed Venture Partners Attention: Andrew Moley 2200 Sand Hill Road Menlo P
August 20, 2020	SC 13G/A	PSNL / Personalis, Inc. / Abingworth LLP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Personalis, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 71535D106 (CUSIP Number) August 18, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule
August 12, 2020	EX-1.1	Underwriting Agreement, dated August 11, 2020, by and among the Company, BofA Securities, Inc., Citigroup Global Markets Inc., and Cowen and Company, LLC, as representatives of the several underwriters named on Schedule II thereto, and a certain stockholder of the Company named on Schedule I thereto. EX-1.1 Exhibit 1.1 EXECUTION VERSION 6,578,947 Shares PERSONALIS, INC. COMMON STOCK, $0.0001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT August 11, 2020 EXECUTION VERSION August 11, 2020 BofA Securities, Inc. Citigroup Global Markets Inc. Cowen and Company, LLC c/o BofA Securities, Inc. One Bryant Park New York, NY 10036 c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 1001
August 12, 2020	424B5	6,578,947 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-239649 Prospectus Supplement (To Prospectus dated July 10, 2020) 6,578,947 Shares Common Stock We are offering 6,578,947 shares of our common stock. Our shares trade on the Nasdaq Global Market under the symbol “PSNL.” On August 10, 2020, the last reported sale price of our common stock was $21.05 per share. We are an em
August 12, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2020 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File N
August 11, 2020	424B5	SUBJECT TO COMPLETION, DATED AUGUST 11, 2020 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-239649 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and accompanying prospectus are not an offer to sell thes
August 6, 2020	EX-10.1	First Amendment to Lease, by and between MENLO PREPI I, LLC and TPI INVESTORS 9, LLC and the Registrant, dated April 8, 2020. Exhibit 10.1 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this “Amendment”) is made as of April 8, 2020 (the “Effective Date”), by and between MENLO PREPI I, LLC, a Delaware limited liability company and TPI INVESTORS 9, LLC, a California limited liability company (collectively, “Lessor”) and PERSONALIS, INC., a Delaware corporation (“Lessee”). RECITALS A.Lessor (as successor in interes
August 6, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) (Commission File Nu
August 6, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38943 Personalis, Inc.
August 6, 2020	EX-99.1	3 PERSONALIS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (in thousands, except share and per share data) Exhibit 99.1 Personalis Reports Second Quarter 2020 Financial Results MENLO PARK, Calif. – August 6, 2020 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today reported financial results for the second quarter ended June 30, 2020. Second Quarter Highlights • Reported record revenues of $19.5 million in the second quarter of 2020 versus $15.8 million in the second quart
July 8, 2020	CORRESP	- CORRESP PERSONALIS, INC. 1330 O’Brien Drive Menlo Park, California 94025 (650) 752-1300 July 8, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Personalis, Inc. Registration Statement on Form S-3 Filed July 2, 2020 File No. 333-239649 Ladies and Gentlemen: In accordance with Rule 4
July 2, 2020	EX-4.8	Form of Common Stock Warrant Agreement and Warrant Certificate. EX-4.8 Exhibit 4.8 PERSONALIS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF PERSONALIS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between PERSONALIS, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws o
July 2, 2020	EX-4.6	Form of Indenture. EX-4.6 Exhibit 4.6 PERSONALIS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Sec
July 2, 2020	S-3	- S-3 S-3 Table of Contents As filed with the U.S. Securities and Exchange Commission on July 2, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Personalis, Inc. (Exact name of registrant as specified in its charter) Delaware 27-5411038 (State or other jurisdiction of incorporation or orga
July 2, 2020	EX-4.10	Form of Debt Securities Warrant Agreement and Warrant Certificate. EX-4.10 Exhibit 4.10 PERSONALIS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF PERSONALIS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between PERSONALIS, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under
July 2, 2020	EX-4.9	Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.9 Exhibit 4.9 PERSONALIS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF PERSONALIS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between PERSONALIS, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under t
May 20, 2020	8-K	Submission of Matters to a Vote of Security Holders 8-K 1 d906229d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2020 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporati
May 7, 2020	10-Q	Quarterly Report on Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38943 Personalis, Inc.
May 7, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 psnl-8k20200507.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorpo
May 7, 2020	S-8	- S-8 S-8 As filed with the Securities and Exchange Commission on May 7, 2020 Registration No.
May 7, 2020	EX-99.1	3 PERSONALIS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (in thousands, except share and per share data) Exhibit 99.1 Personalis Reports First Quarter 2020 Financial Results MENLO PARK, Calif. – May 7, 2020 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today reported financial results for the first quarter ended March 31, 2020. First Quarter Highlights • Reported record revenues of $19.2 million in the first quarter of 2020 versus $14.1 million in the first quarter of 2
May 7, 2020	EX-10.1	Amendment to Employment Terms Letter, by and between John West and the Registrant, dated May 6, 2020. Exhibit 10.1 FIRST AMENDMENT to EMPLOYMENT TERMS AGREEMENT Dated June 2, 2019 Between John West and Personalis, Inc. Pursuant to the modification provision of that certain Employment Terms letter agreement between Personalis, Inc. (the “Company”) and John West (“Mr. West”) dated June 2, 2019 (the “Agreement”), the Company and Mr. West hereby amend the Agreement as set forth below, effective as of
May 7, 2020	EX-99.1	Personalis, Inc. 2020 Inducement Plan and forms of agreements thereunder. EX-99.1 Exhibit 99.1 PERSONALIS, INC. 2020 INDUCEMENT PLAN ADOPTED BY THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS: MAY 4, 2020 1. GENERAL. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related
April 3, 2020	DEFA14A	PSNL / Personalis, Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2

PSNL / Personalis, Inc. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

الإحصائيات الأساسية

SEC Filings

SEC Filings (Chronological Order)

Other Listings